Synthesis Of Multilayered Microparticles For Targeted Drug Delivery by Mercer, Elizabeth
Purdue University
Purdue e-Pubs
Open Access Theses Theses and Dissertations
Fall 2014




Follow this and additional works at: https://docs.lib.purdue.edu/open_access_theses
Part of the Biomedical Engineering and Bioengineering Commons
This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.
Recommended Citation







SYNTHESIS OF MULTILAYERED MICROPARTICLES FOR TARGETED DRUG 
DELIVERY 
A Thesis 




Elizabeth Mercer  
In Partial Fulfillment of the 
Requirements for the Degree 
of 
Master of Science in Biomedical Engineering 
December 2014  
Purdue University 




















I would like to begin by thanking all my family and friends for their support 
throughout this process. My mom, Katherine Armstrong and dad, Brian Mercer have 
truly supported me throughout all my endeavors. The love and support of Walter and 
Daphne Mercer have also been essential through this process. I would like to Becky, Jim, 
and Dexter Lesh for all the good times and support that they have given me. 
 I would like to thank all the Panitch lab members for all the good times and 
collaboration. Specifically, Jim McMasters who was always there to answer my questions 
and gave me good suggestions throughout my experiments. Also, I would like to thank 
Scott Poh for all his help with teaching me to use various imaging devices. I am excited 
to see all the future great works of the Panitch lab members. I would like to thank to 
everyone in the Weldon School of Biomedical Engineering and Purdue University for 
shaping a wonderful undergraduate and graduate career  
 Finally, I am most grateful for all my committee members: Dr. Alyssa Panitch, 
Dr. James Leary, and Dr, Kinam Park for their invaluable input and suggestions to future 
this work. But truly all this would not have been possible without my major professor, 
Dr. Panitch, who is brilliant and provided great insight and suggestions to my project. I 






TABLE OF CONTENTS 
Page 
ABSTRACT ....................................................................................................................... vi 
CHAPTER 1   INTRODUCTION. ..................................................................................... 1 
1.1 Drug Delivery Systems ..............................................................................................1 
1.2 Microparticle Design ..................................................................................................2 
1.2.1 Hydrophobic Polymer Core ............................................................................. 3 
1.2.2 Hydrophilic Polymer Shell .............................................................................. 4 
1.3 Microparticle Application ..........................................................................................6 
1.3.1 Atherosclerosis Background ............................................................................ 6 
1.3.2 Collagen Binding Peptide ................................................................................ 6 
1.4 Microparticle Synthesis Method ................................................................................8 
1.4.1 Common Synthesis Methods ........................................................................... 8 
1.4.2 Park Templating Method ................................................................................. 8 
1.5 References ................................................................................................................11 
CHAPTER 2. METHODS ............................................................................................. 16 
2.1 PVA Template Synthesis .........................................................................................16 
2.1.1 Preparation of PVA Templates ...................................................................... 16 
2.2 Preparation of Polymer Solution ..............................................................................17 
2.3 Microparticle Synthesis ............................................................................................18 
2.3.1 Functionalizable Microparticle Synthesis [2] ................................................ 18 
2.3.2 Negative Control Microparticle Synthesis [2] ............................................... 19 
2.4 Attachment of Peptides ............................................................................................20 
2.4.1 Attachment of FITC-SILY ............................................................................ 20 







2.5 Validation Experiments ............................................................................................21 
2.5.1 Validation of FITC –SILY Attachment to Microparticle Surface ................. 21 
2.5.2 Quantification of FITC-SILY Attachment to Microparticles ........................ 21 
2.5.3 Validation of Microparticles’ Collagen Binding Capabilities ....................... 23 
2.6 References ................................................................................................................24 
CHAPTER 3. RESULTS ............................................................................................... 25 
3.1 Validation of FITC –SILY Attachment to Microparticle Surface ...........................25 
3.2 Quantification of FITC-SILY Attachment to Microparticles ..................................28 
3.2.1 Standard Curve .............................................................................................. 28 
3.2.2 Results of Quantification of FITC-SILY Attachment to Microparticles ....... 29 
3.3 Results of Microparticles’ Collagen Binding Capabilities .......................................31 
CHAPTER 4. DISCUSSION ......................................................................................... 33 
4.1 Adapting the Park Templating Method ....................................................................33 
4.1.1 Order of Assembly ......................................................................................... 33 
4.1.2 PVA as a Template ........................................................................................ 33 
4.1.3 Multilayered Potential ................................................................................... 34 
4.1.4 Incorporating Hydrophilic Polymers ............................................................. 35 
4.1.5 Comparison to Other Hydrogel Synthesis Procedures .................................. 35 
4.2 Evaluation of Microparticles ....................................................................................37 
4.2.1 Validation of FITC –SILY Attachment to Microparticle Surface ................. 37 
4.2.2 Quantification of FITC-SILY Attachment to Microparticles ........................ 37 
4.2.3 Validation of Microparticles’ Collagen Binding Capabilities ....................... 39 
4.3 Microparticle Degradation Observations .................................................................40 









Mercer, Elizabeth. M.S.B.M.E., Purdue University, December 2014. Synthesis of 
Multilayered Microparticles for Targeted Drug Delivery. Major Professor: Alyssa 
Panitch. 
 
Microparticles have been shown to be valuable in targeted drug delivery which can 
lead to an increased dose delivered to a targeted location, reduced patient side effects, and 
improved patient outcomes. The designed multilayered microparticles have the clinical 
application to deliver hydrophobic drugs to a targeted area. The composition of the 
microparticles consists of a poly-lactic acid (PLA) polymer core surrounded by a polymeric 
shell composed of Poly(lactic-co-glycolic acid)-Poly(ethylene glycol)-Maleimide(PLGA-
PEG-Mal). The maleimide promotes conjugation of the collagen binding peptide, SILY. 
Targeting to type I collagen allows for this microparticle system to attach to exposed collagen 
in atherosclerotic vessels. 
A novel templating method was used to synthesize uniform microparticles with 
manufacturing scale-up potential. Modification of the templating method was necessary to 
synthesize hydrophilic, multi-layered microparticles. The experimental results verified and 
quantified the presence of attached fluorescent SILY to the maleimides present on the surface 
of the microparticles as well as the microparticles' attachment to type I collagen. These 
results signify that the designed microparticles have the potential to deliver hydrophobic 






CHAPTER 1. INTRODUCTION 
1.1 Drug Delivery Systems 
Drug delivery systems advancements have led to the treatment of a variety of 
diseases. Drug delivery systems are defined as “engineering technologies for the targeted 
delivery and/or controlled release of therapeutic agents” [1]. Nanoparticles and 
microparticles are growing as a major component of novel drug delivery processes. Nano and 
microparticles have been shown to be valuable in the following: 
 targeted drug delivery to diseased tissues 
 decreased dose delivered systemically and potential tissue damage [2] 
 increased dose delivered locally to diseased tissues 
 reduced side effects in sensitive, non-target tissues [2] 
 controlled drug release [3] 
 improved patient outcomes 
Ultimately, nano and microparticles have the potential to provide improved therapy and 
diagnostics to more patients. 
Due to the increased amount of research performed on nano systems, it is important 
to understand the distinction between nano and microparticles. Nano and microparticles are 
so referred based on the distinction between dimensions in terms of nanometer and 
micrometers respectively; these size differences can have numerous effects on the mode and 






 they are less likely to aggregate and potentially cause occlusions [4]  
 they have the potential for higher drug loading  
 they have a longer time for degradation  
Microparticles have a tendency to remain localized in diseased tissue after direct 
injection [4]. For example, microparticles with 5-250 µm diameter remained in the 
peritoneum of mice for at least two weeks compared to the same mass of nanoparticles which 
were cleared from the peritoneum in two days [4, 5]. Microparticles are the chosen drug 
delivery systems in order to provide increased long-term treatment to diseased areas. 
Similar to any system, microparticles have their limitations. Smaller particles have 
better binding affinity compared to larger particles [4]. The binding affinity can be combated 
by adding a targeting ligand, such as a peptide, to the outside of the microparticle to increase 
binding to particular cells. Also, larger microparticles have the potential to cause 
embolization within blood vessels. They may lodge in the pulmonary vasculature causing a 
pulmonary embolism or may lodge in end organs causing ischemia and possibly necrosis. 
The exact particle size to prevent this is unknown, but large quantities of 4-5µm particles 
were injected into the carotid arties of mice without causing detectable problems [4, 6]. 
Based on previous research, 5µm is the upper limit for target microparticle size to prevent 
embolization potential. Due to the numerous benefits of microparticles as well as the methods 
to combats their limitation, microparticles are the chosen drug delivery system. 
 
1.2 Microparticle Design 
Microparticles can be adaptable with the delivery of different drugs to various 






microparticles in this study consisted of a hydrophobic polymer core surrounded by a 
hydrophilic polymer shell with attached targeting peptides shown here in Figure 1.1.  
 
Figure 1.1 Depiction of the overall designed microparticle system. The blue and orange 
regions represent the hydrophobic core surrounded by the green hydrophilic shell. The 
polymer shell also contains a reactive group which allows for the attachment of the 
targeting peptide.  
 
This amphiphilic system provides many advantages to this drug delivery system by 
having the potential to incorporate a hydrophobic drug within the hydrophobic polymer core.  
Hydrophobic drugs tend to have poor solubility in the body’s aqueous environment [2]. The 
amphiphilic system enhances drug solubility by providing both a hydrophilic environment for 
the body to interact with and a hydrophobic environment to encapsulate the drug [2]. 
 
1.2.1 Hydrophobic Polymer Core 
The hydrophobic polymer core is composed of poly-lactic acid (PLA). PLA is 
commonly used for controlled drug delivery because it is a well-known, biodegradable, 






properties, which inhibited diffusion into the hydrophilic PVA template and provided the 
structural integrity for the microparticles.  
The hydrophobic effect of the PLA core promotes interaction with the hydrophobic 
region of the polymer shell. Poly(lactic-co-glycolic acid)- Poly(ethylene glycol)- Maleimide 
(PLGA-PEG-Mal) composes the polymer shell, however the hydrophobic PLGA 
incorporates into the core with which it is miscible. PLGA provides many benefits in medical 
systems due to its biodegradability, biocompatibility, predictability of degradation, ease of 
fabrication, and FDA approval [9, 10]. 
 
1.2.2 Hydrophilic Polymer Shell 
Polymer shell coatings provide many advantages to drug delivery systems. A 
significant advantage is that these shells provide drug diffusion control which slows the 
release of drug from the core of the microparticle [3]. The polymer used to form the shell is 
Poly(lactic-co-glycolic acid)-Poly(ethylene glycol)–Maleimide (PLGA-PEG-Mal). While the 
PLGA intercalates into the core to hold the shell in place, the PEG remains largely within 
PEG-rich layer at the particle surface.  Significant research has been performed on the use of 
PLGA and PEG in drug delivery systems. These polymers are both biodegradable and their 
rate of degradation is linked to the chain length [11]. PLGA-PEG microparticles have been 
synthesized to deliver pulmonary drugs [12], anti-inflammatory drugs [13], and 
neurotrophic factor used to treat Parkinson’s Disease [14]. Based on the numerous benefits 
of PLGA and PEG, these polymers are ideal for use as a polymeric shell for this 
microparticle system. 
Since the hydrophobic PLGA incorporated into the core, the hydrophilic PEG is the 






inhibits particle aggregation within the body [15]. PEG coatings have been found to be non-
immunogenic, so they provide protection against interaction with the blood components, 
which induce the removal of the foreign particles from the blood [16, 11]. Therefore, the 
circulation time of microparticles with PEG ensures that the microparticles have sufficient 
time to target and deliver therapy to the diseased areas within the blood vessels.  
The PEG has a terminal maleimide functional group allowing for attachment of 
targeting peptides containing a sulfhydryl or amine. The PEG is highly flexible which allows 
for peptide conjugation to the maliemide without significant steric hindrance of the peptide 
ensuring that it is available to bind to its target [16]. For reaction mixtures with a pH greater 
than 8.5, the maleimide favors a reaction with a primary amine, but also the alkaline pH 
increases the rate of hydrolysis to a non-reactive maleamic acid [17]. For reaction mixtures 
with a pH between 6.5 and 7.5, the maleimide reacts with a sulfhydral to form a stable, 
nonreversible thioether linkage [17]. All experiments were executed at a pH of 7.4 to enhance 
maleimide reaction with sulfhydryl groups. Buffers or agents with free sulfhydryls or free 
amines should not be used in the synthesis of these microparticles as they have the potential 
to react with the free maleimides. This overall microparticle design has the potential to be 
used to deliver various hydrophobic drugs to various targeted tissues within the body based 






1.3 Microparticle Application 
1.3.1 Atherosclerosis Background 
Atherosclerosis is most commonly characterized by the accumulation of lipids and 
fibrous elements in the large arteries; however, it is now recognized as a chronic 
inflammatory disease. [18, 19]. Atherosclerosis has the clinical implication of a build-up 
of plaque along artery walls which potentially leads to heart attack, stroke, or even death 
[18, 20]. Collagen Type I is a major component of deep vessel injury on an 
atherosclerotic vessel injury present after balloon angioplasty or plaque rupture [21]. The 
target diseased area for these particular microparticles is atherosclerotic tissue along vessel 
walls.  
 
1.3.2 Collagen Binding Peptide 
Collagen is the most abundant protein in animals [23]. It is located in and maintains 
the integrity of the extracellular matrix and connective tissue [23, 24]. Due to the 
mechanical resilience of collagen, it has become highly used for different biomedical 
applications including: biomimetic cell culture scaffold and tissue engineering [25, 26]. 
There are at least twenty-nine types of collagen, but types I, II, and III are the most 
abundant [27]. The building block of collagen is tropocollagen which is composed of 
three helical polypeptide chains that containing the triplet Gly-X-Y [27, 23]. Type I 
collagen has many benefits including its ability to self-assemble in vitro, resilient 
mechanical properties, and hierarchical structure [26]. The microparticles will be tested 
to see if attachment occurs with type I collagen from rat tail [28]. Rat tail tendon-rich 






fundamental collagen unit of rat tail type I collagen is a long, thin protein that consists of 
three coiled subunits [24]. Due to the abundance of collagen in the body, there are many 
diseases associated with collagen that would benefit from a drug delivery system 
targeting collagen. For this reason, a collagen binding peptide was then attached to the 
polymer shell to promote collagen type I attachment. 
In order to effectively target type I collagen, a collagen binding peptide can be 
attached to the shell of the microparticles. Various synthetic peptidoglycans that bind to 
type I collagen have been or are currently being synthesized in the Panitch laboratory 
[29-31]. During development of the peptidoglycans, the peptide sequence 
RRANAALKAGELYKSILYGC (SILY) was shown to bind with Collagen Type I on its 
own or when bound to hydrophilic polymers [31]. SILY was derived from the platelet 
receptor to collagen type I and was modified to use a cysteine sulfhydryl group for 
conjugation to polymers [31]. The sulfhydryl group at the C-terminus of SILY allows for 
conjugation to the maleimides available on the shell of the microparticles. For this 
reason, SILY was the chosen collagen-binding peptide for this system.  
 
Figure 1.2 Depiction of the overall microparticle system including the collagen binding 






1.4 Microparticle Synthesis Method 
1.4.1 Common Synthesis Methods 
To date, microparticles have been prepared by emulsion-solvent evaporation, phase 
separation, interfacial polymerization, spray drying, emulsion extraction process, jet milling 
technique, and fluidization [10]. The common emulsion methods result in particles with 
different size distributions [32]. The uniformity of the size of the particles has a significant 
influence on the drug release rates. Particle size can be controlled by various factors for the 
conventional synthesis methods including: varying polymer concentration [33] and choice of 
polymer chemistry [34]. Various studies have found difficulties in producing uniformly sized 
particles for drug release studies [33, 35]. However, some researchers have shown that larger 
particles release encapsulated compounds more slowly and over an extended time period with 
the other properties (molecular weight, initial porosity, drug distribution with the sphere) 
being equal [34]. Drug release studies have shown that the initial drug release rates decreased 
with increasing particle diameter due to the decrease in surface/volume ratio with increasing 
size [34]. This resulted in a concave downward and sigmoidal release profile curve for small 
and large particles respectively [34]. Thus, the uniformity of microparticles is essential to 
understanding and controling drug release rate profiles. Fortunately, a templating method 
developed by Dr. Kinam Park’s lab at Purdue University has shown promise in producing 
uniformly sized particles among other benefits.  
 
1.4.2 Park Templating Method 
The particle size can be easily controlled using the Park templating method just with 
the use of different template sizes ranging from 6-50µm [36]. The template used in these 






also has the scale-up potential for manufacturing using the new automated microparticle 
synthesizer, the SpinSwiper [36]. 
The Park templating method (shown in Figure 1.3) produces microparticles by using a 
silicon master template. The silicon master template is then used to form a degradable 
template made of gelatin or poly(vinyl alcohol) (PVA). The desired polymer solution is 
poured into the gelatin or PVA template with the excess solution removed. The solvent in the 
polymer solution evaporates, and the gelatin or PVA can be melted and removed leaving 
column shaped particles. Since the shape of the particles has previously been limited to a 
sphere, the Park templating method will allow research of different particle shapes on 
biological responses. Another benefit of this synthesis method is that the gelatin mold 






Figure 1.3 Schematic of the Park Microparticle Synthesis Process [32]. A: The silicon master 
template is made by photoliography. B: A warmed gelatin solution is cooled on the master 
template. C: The master template is peeled away exposed open wells to make uniform 
microparticles. D: The wells are filled with polymer solution and the excess solution is 
removed with a razor blade. E: The gelatin is heated and removed with centrifugation. And, 
the final product of the microparticles remains. 
 
In order to adapt this procedure to synthesize the multilayered microparticles, the 
PLGA-PEG-MAL and PLA are added in separate layers. The hypothesis with this procedure 







And, the hydrophobic PLGA would preferentially remained exposed to the air interface and 
would be available to intercalate into the core of the particles when the PLA solution was 
added to the template. The final PEG-PLGA layer to the template particle surface would 
allow for complete coating of the PLA particles with a PEG shell.  Adapting the Park 
templating method for synthesizing multilayered microparticles could be used to treat a 
variety of diseases in various locations of the body. 
The overall goal of this research is to develop a novel microparticle drug delivery 
system synthesized by adapting the Park templating method.  Chapter 2 describes the adapted 
synthesis method and the methods for analyzing the synthesized microparticles. Chapter 3 
shows the obtained results of verifying surface maleimides and the collagen binding 
capabilities of the microparticles. Chapter 4 describes the benefits of this microparticle 
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CHAPTER 2. METHODS 
2.1 PVA Template Synthesis 
Poly(vinyl alcohol) (PVA) was purchased from Sigma-Aldrich. The 4% (w/v) PVA 
was dissolved in 500mL of deionized water with constant stirring at 60˚C. After full 
dissolving of the PVA, 500mL of ethanol was slowly added to the PVA solution with 
constant stirring at 60˚C. The PVA solution was left at room temperature. 
 
2.1.1 Preparation of PVA Templates 
A Polydimethylsiloxane (PDMS) template with 50µm column height and width 
wells was purchased from Akina, Inc (Cat # AKPDMS-50). The wells were formed with 
photolithography. The PDMS template was placed on a glass slide with the wells facing 
upright. Then, 8mL of PVA solution was pipetted onto the side of the PDMS template 
containing the wells. The PVA solution was allowed to dry at room temperature 
overnight on a flat surface. The dried PVA template was then peeled away from the 
PDMS template exposing the formed wells. The templates were stored in a dry, covered 
container until used. The PDMS molds were cleaned after approximately 30 pours with 







2.2 Preparation of Polymer Solution 
 The acid terminated polymer, poly(DL-Lactide) (PLA), was purchased from 
Lactel Absorbable Polymers (CAT #B6014-1). The PLA has an inherent viscosity 
between 0.15-0.25kDa [1]. A 20% w/v solution of PLA in Dichloromethane (DCM) was 
prepared in a glass vial. And the solution was mixed for 30 minutes. This PLA solution 
was prepared to later form the core of the microparticles. 
The Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-maleimide (PLGA-PEG-
Mal) was purchased from Akina, Inc. (Cat #AI20). The molecular weight of the PLGA-
PEG-Mal was 20:5 kDa. The PLGA-PEG-Mal was prepared as a 5% solution in DCM. 
The polymer-solvent solution was mixed for 30 minutes. The PLGA-PEG-Mal was 
prepared to later form the shell of the functionalizable microparticle 
 The Methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) (mPEG-
PLGA) was purchased from Akina, Inc. (Cat #AK02). The molecular weight of the 
mPEG-PLGA was 2:4.11 kDa. The mPEG-PLGA was prepared as a 5% solution in DCM 
and was mixed for 30 minutes. The mPEG-PLGA was prepared to later be used as the 







2.3 Microparticle Synthesis 
The PVA templates were prepared for microparticle synthesis by cutting each PVA 
template into approximately 4 strips without any bubbles in the template. The templates 
were each placed onto an individual glass slide and taped on the top and bottom to 
prevent shifting. 
 
2.3.1 Functionalizable Microparticle Synthesis [2] 
The functionalizable microparticles were composed of a PLA core with a PLGA-
PEG-Mal shell. These functionalizable microparticles were formed by pippetting 9µL of 
PLGA-PEG-Mal/DCM onto one PVA strip. The polymer solution was then quickly 
spread evenly around the PVA strip. This process was repeated for each strip. The 
polymer solution was allowed to dry for 15 minutes.  
The PLA solution was used to form the core of the microparticles on top of the 
PLGA-PEG-Mal layer. After allowing the PLGA-PEG-Mal solvent to evaporate, 9µL of 
20% PLA solution was pipetted onto one strip and spread evenly with a razor blade. This 
step was repeated for each strip. The PLA solution was allowed to dry for 15 minutes.  
Then, the final layer of the shell was applied by pippetting 9µL of the 5% PLGA-PEG-
Mal solution onto a single PVA strip and spreading evenly with a razor blade. This was 
repeated for each strip and then the polymer solution was allowed to dry for 15 minutes. 
After the drying process, the strips were cut using a razor blade to remove them 







2.3.2 Negative Control Microparticle Synthesis [2] 
The negative control particles were synthesized with the same steps of the 
functionalizable microparticles except in place of the PLGA-PEG-Mal, the mPEG-PLGA 







2.4 Attachment of Peptides 
2.4.1 Attachment of FITC-SILY 
The FITC-Ahx-RRANAALKAGELYKSILYGC (FITC-SILY) was purchased as 
a custom order from GenScript. A 2mg/mL solution of FITC-SILY with 1x Phosphate 
Buffered Saline (PBS) with a pH of 7.4 was prepared in the dark. This solution was 
mixed for one hour. The FITC-SILY solution was placed on top of the strips in the 50 mL 
beaker and was stirred for one hour at room temperature in the dark. This allowed the 
PVA template to fully dissolve and the FITC-SILY to conjugate to the available 
maleimide groups at the particle surface. The dissolved PVA and excess peptide were 
removed by centrifuging the sample at 5,000rpm for 5 minutes and discarding the 
supernatant. A wash using 1x PBS was repeated three times. The microparticles were 
then viewed under a light microscope to view the integrity of the particles and lyophilized 
overnight. The microparticles were stored at -20˚C. The attachment of FITC-SILY was 
essential for the later validation of FITC-SILY on the surface of the microparticles and 
for the quantification of FITC-SILY attachment. 
 
2.4.2 Attachment of SILY 
The RRANAALKAGELYKSILYGC (SILY) was purchased as a custom order 
from GenScript. The same procedure was used for the attachment of SILY that was 
described for the attachment of FITC-SILY except that the FITC-SILY was prepared at a 







2.5 Validation Experiments 
2.5.1 Validation of FITC –SILY Attachment to Microparticle Surface 
The presence of attached FITC-SILY was validated using an FV1000/IX81 
confocal microscope. Samples of the FITC-SILY-Mal-PEG-PLGA and the negative 
control microparticles were placed onto glass slides. These slide were analyzed used the 
488 laser of the confocal microscope for review.  
 
2.5.2 Quantification of FITC-SILY Attachment to Microparticles 
The procedure for the attachment of FITC-SILY for this experiment differed 
slightly from the procedure described above because it was noted that there was some 
FITC-SILY non-specific interactions and peptide clumping. The only differences to the 
procedure described above are listed here. To prevent non-specific interaction of FITC-
SILY with negative control microparticles, a methyl-PEG-PLGA with a molecular 
weight of 5,000:4,000 Da (Cat# AK30) was purchased from Akina Inc and used to form 
the polymer shell of the negative control microparticles. To reduce the clumping, a 
0.0156mg/mL solution of FITC-SILY in 1x Phosphate Buffered Saline (PBS) with a pH 
of 7.4 was prepared in the dark with a small amount of Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP-HCl) [3] (Thermo Scientific (Product# 20490)). This solution was 
mixed for one hour. Then one wash was performed to remove any undissolved FITC-
SILY by centrifuging at 5,000rpm for 5 minutes. The FITC-SILY solution was placed on 
top of the strips in the 50 mL beaker and was stirred for one hour at room temperature in 
the dark. This allowed the PVA template to fully dissolve and the FITC-SILY to 







and excess peptide were removed by centrifuging the sample at 5,000rpm for 5 minutes 
and discarding the supernatant. A wash using 1x PBS was repeated three times. The 
microparticles were then viewed under a light microscope to view the integrity of the 
particles and lyophilized overnight. 
The following day, 100µL of 1xPBS was placed into twelve wells of a black 96-
well plate with a clear bottom. 0.06mg of experimental and negative control 
microparticles was measured and placed into individual wells in the dark. Six replicates 
were analyzed for the experimental and negative control groups. The 96-well plate was 
analyzed with a SPECTRAmax M5 Plate Reader with the following settings: 
 Endpoint reading 
 Fluorescence – bottom read 
 Excitation: 495nm 
 Emission: 519 
 Automix: Once for 5 seconds before first read 
 Calibrate: On 
 PMT: Medium 
 Settle Time: Off 
 Column Priority 
 C. Speed: Normal 








2.5.3 Validation of Microparticles’ Collagen Binding Capabilities 
The ability for the SILY-Mal-PEG-PLGA microparticles to bind to collagen was 
validated using a collagen-binding assay. Collagen I 96 clear well plates were purchased 
from Fisher Scientific (Cat # 08-774-1). The collagen plate was blocked with 2% BSA to 
prevent non-specific binding for one hour at 37˚C. The plate was washed three times with 
1xPBS. The SILY-Mal-PEG-PLGA and negative control microparticles (Me-PEG-
PLGA) were separately suspended in 1x PBS at a pH of 7.4 at a concentration of 
1.4mg/mL. Then, 100µL of microparticle solution was pipetted into each of 6 wells of the 
collagen plate. The 96-well plate was covered and incubated for 30 minutes at 37˚C. The 
wells were then washed three times with 1x PBS. The microparticles present in each well 
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CHAPTER 3. RESULTS 
3.1 Validation of FITC –SILY Attachment to Microparticle Surface 
The described protocol was developed after first performing the published Park 
method to synthesize microparticles that are composed entirely of PLGA [3]. The results 
from this preliminary data showed that particles had a tendency to agglomerate in the water 
solvent most likely due to the hydrophobic nature of PLGA. This agglomeration made 
imaging and the size analysis of individual particles difficult. This agglomeration was not 
observed with the PLGA-PEG particles in water indicating a presence of PEG on surface that 
forms hydrogen bonds with the water thus preventing agglomeration of the particles. The 
dispersed particles can be seen clearly in Figure 3.1 shown below. The presence of the 
hydrophilic PEG on the surface also provides the opportunity to attach peptides, via a 
reactive PEG end group, to the particle surface to encourage particle binding to a target 
molecule. 
 The Mal-PEG-PLGA microparticles shown in Figures 3.2 and 3.3 below validate 
that the FITC-SILY is interacting with the surface of the particles. This interaction is 
most probably a reaction between the maleimide on the microparticle and the free 
cysteine in the SILY. Figures 3.2-3.3 show distinctive green fluorescent rings around a 
non-florescent polymer core. This same lack of fluorescence was seen in the negative 
control microparticles in Figure 3.4, suggesting that the peptide is able to conjugate to the 








Figure 3.1 Light microscope images of the SILY-Mal-PEG-PLGA microparticles 
shown on the left. The right image shows the negative control microparticles 
composed of Me-PEG-PLGA.  
 
  
Figure 3.2 Mal-PEG-PLGA microparticles reacted with FITC-SILY. Microparticles 
were analyzed using a 488 laser on a confocal microscope. The microparticles are 
shown here in an overlayed image with white and fluorescent light. The 
microparticles shown in these two images represent microparticles in different 
batches on different days. This experiment was run in triplicate to ensure consistency 









Figure 3.3 Negative control microparticles visualized with the confocal microscope 







3.2 Quantification of FITC-SILY Attachment to Microparticles 
3.2.1 Standard Curve 










Figure 3.4: FITC-SILY Standard Curve graph used to quantify FITC-SILY 
attachment to microparticles.











































3.2.2  Results of Quantification of FITC-SILY Attachment to Microparticles 
 Table 3.2: Experimental results showing the concentration of FITC-SILY Attached 
to experimental and negative control microparticles. Table Key: Exp= Experimental 
Samples, NC= Negative Control Samples, Avg=Average. 
 
The statistics were analyzed for the quantification experiment of FITC-SILY 
attachment to micorparticles. A normality test was first performed on each data group 
to determine normality. The normal data sets were analyzed using a two sample T-
test, while the non-normal data was analyzed using a Mann-Whitney test.  
 
Table 3.3: Statistical analysis showing a statistical difference between the 
experimental and negative control samples.  




1 Mann-Whitney 0.0051 0.05 Yes 
2 Mann-Whitney 0.0082 0.05 Yes 
3 2 sample t-test 0.016 0.05 Yes 










1 Exp 716 473 285 682 3034 293 913.7 1054.8 0.00162737 
  NC 162 209 171 269 178 180 194.8 39.6 0.000189537 
2 Exp 580 223 497 306 166 420 365.2 161.0 0.00053036 
  NC 133 106 109 205 96 95 124.0 42.1 4.79593E-05 
3 Exp 474 126 324 264 231 88 251.2 139.8 0.0003024 
  NC 40 54 49 55 58 77 55.6 12.4 -0.000088736 
4 Exp 285 146 192 271 169 90 192.1 74.9 0.000184282 








Figure 3.5: Graphical representation of the concentration of attached FITC-SILY to 
the experimental microparticles compared to the negative control microparticles.  
 
Figure 3.5 does not include data point from Experiment 1 Sample 5 from the 
experimental microparticles because it is an outlier from this data. This outlier can be 













































3.3 Results of Microparticles’ Collagen Binding Capabilities 
The ability of the attachment of a targeting peptide may greatly facilitate the 
application of the designed microparticles for drug delivery. SILY-Mal-PEG-PLGA 
microparticles were found to be attached to the collagen type I bound plate by 
counting whole microparticles attached to the collagen plate. Microparticle 
particulates were excluded from the microparticle count.  
 






A statistical analysis was performed on the collagen binding capability data. 
First, a normality test was run on all sets of data to determine if the data was normal. 
A two sample T-test was performed for normal data, and a Mann-Whitney test was 
performed for non-normal data. 
 








0.005 0.05 yes 
Mann-
Whitney 
0.0247 0.05 yes 
Experiment Samples 1 2 3 4 5 6 Average St Dev 
 1 Experimental 25 13 15 12 31 31 21.17 8.13 
 Negative 
Control 
2 1 1 5 6 5 3.33 2.05 
2 Experimental 10 8 8 17 5 1 8.17 4.88 
 Negative 
Control 








Figure 3.6: Bound experimental (SILY-Mal-PEG-PLGA) microparticles attached to 











CHAPTER 4. DISCUSSION 
4.1 Adapting the Park Templating Method 
4.1.1 Order of Assembly 
There are many unique aspects of the Park templating synthesis method including the 
order of assembly. The designed microparticles are composed of an outer most layer of 
collagen binding peptides attached to a polymer shell. The polymer shell is composed of 
PLGA-PEG-Mal. The maleimides allow for the attachment of the collagen binding peptide. 
The polymer shell forms as an integrated layer with the hydrophobic PLA in the core of the 
microparticle and presents the hydrophilic PEG on the outside of the particle to form a 
polymeric shell as shown in Figure 1.2. The hydrophobic drug can be encapsulated within the 
polymeric shell. The order of assembly for these microparticles is different from the tradition 
reverse order of assembly for many nanomedical systems. Many systems are manufactured 
from the core to the outermost shell in the reverse order that the layers are actually used 
within the body. Due to the templating method used, the order of synthesis is a layer of the 
polymeric shell followed by a layer of the hydrophobic drug then a final layer of the 
polymeric shell. The assembly ends with the addition of the collagen binding peptide. 
 
4.1.2 PVA as a Template 
As described in the introduction, gelatin was the suggested template to use during 







microparticle synthesis, however no fluorescence was seen after attempting to conjugate 
thiol-terminated fluorescent peptide to surface maleimide groups on the template. 
This suggested that functionalizable maleimides were not present on the surface of the 
microparticles. It was hypothesized that the maleimide was reacting with the gelatin, 
since gelatin contains lysine which contains a free amine group [2]. During the time of 
solvent evaporation or when the gelatin was being dissolved away from the formed 
particles, it is possible that the maleimides were reacting with the lysine in the gelatin. 
PVA has been used to synthesis particles in other studies and does not contain groups that 
are reactive with maleimide. For this reason, PVA template was chosen to prevent the 
unwanted maleimide reaction with the template. Microparticles synthesized using a PVA 
template allowed for successful attachment of FITC-SILY to the maleimide on the 
surface of the microparticles 
 
4.1.3 Multilayered Potential 
The three layers of polymers that compose these microparticles allow for a unique 
drug delivery system. The unique layers of the microparticle allow for different functions 
to be present within one delivery system. The hydrophilic shell prevents agglomeration of 
the microparticles and enhances the interaction with the body’s aqueous environment. 
The hydrophobic polymer core allows for the incorporation of hydrophobic drugs in 
future experiments. The designed procedure can be modified to include more layers 
through decreasing the polymer concentrations. The potential for adapting this procedure 
is limitless and can include layers to enhance imaging of the microparticles, pH 







4.1.4 Incorporating Hydrophilic Polymers 
Previous experiments using the Park templating method used the hydrophobic 
polymer PLGA and/or PLGA-drug combinations for microparticle synthesis [1, 3]. So, 
the Park templating method needed to be adapted for synthesizing microparticles with a 
hydrophilic PEG shell. PLGA with drug combinations was shown to maintain its 
structure as a cylinder or as alphabet letters and was found not to diffuse into the template 
[1]. Diffusion into the hydrophilic template was prevented because a hydrophobic 
nonpolar solution was used. A solely hydrophilic solution would be miscible with the 
template and diffuse into the template. So, the PLGA-PEG-Mal provides the hydrophobic 
PLGA and the hydrophilic PEG that when the solvent is slowly evaporated from the 
polymer solution, the PEG interacts with the PVA and the PLGA is exposed to the air 
thus forming a core shell in the process. Overall, the hydrophilic shell will prevent 
aggregation in the body and specifically in the blood system. 
 
4.1.5 Comparison to Other Hydrogel Synthesis Procedures 
The Park templating method varies greatly from other methods of microparticle 
synthesis such as oil immersion techniques. However, the molding technique for 
microparticle synthesis represents a similar synthesis method. For the molding technique 
by Yung and Li, a polymer is poured into a mold of any shape and size. A gelling agent 
or temperature change causes the polymer microparticle to gel, and the microparticles can 
be removed from the mold [4]. This molding techniques has similar benefits to the 
templating method in that uniform particles form, procedure is simple and inexpensive, 







reactive fluorescein to the microparticles using chitosan’s abundant amine groups 
showing the microparticles’ targeting ligand conjugation potential [5]. This molding 
technique shows an example of functionalizable microparticle composed of PEG using a 
hydrogel synthesis procedure. Future studies could analyze the use of chitosan-PEG use 







4.2 Evaluation of Microparticles 
4.2.1 Validation of FITC–SILY Attachment to Microparticle Surface 
The hypothesis of this validation experiment was that FITC-SILY would attach to 
the surface of the microparticles through a reaction with the maleimide and the cysteine 
in the SILY. The results of the validation of FITC-SILY attachment show microparticles 
with a distinct fluorescent FITC-SILY shell around a non-florescent core. The non-
florescent core represents the non-reactive PLA and PLGA. The FITC-SILY florescent 
shell indicates that the SILY is reacting with the free maleimides present on the surface 
of the microparticles. Figure 3.3 does show minimal fluorescence on the negative control 
microparticles, however compared to the experimental microparticles there is 
significantly more fluorescence. This minimal fluorescence seen can be attributed to 
some non-specific interactions. The confirmed peptide binding capabilities show that this 
microparticle system has the potential to be a platform for attachment of any peptide 
containing a free thiol or amine. 
 
4.2.2 Quantification of FITC-SILY Attachment to Microparticles 
The hypothesis of this quantification experiment was that there would be a 
statically higher concentration of attached FITC-SILY for the experimental 
microparticles (Mal-PEG-PLGA) in comparison to the negative control particles 
(Methyl-PEG-PLGA). The FITC-SILY concentration of 2mg/mL that was used in the 
Validation of Functionalizable Surface Maleimide experiment was shown to 
incompletely dissolve in PBS leaving free unattached dye that then contaminated the 







optimal FITC-SILY concentration and preparation method for attachment and 
quantification. Different concentrations of FITC-SILY were prepared at concentrations 
between 0.0625 and 0.0078 mg/mL because these concentrations left the least amount of 
undissolved FITC-SILY. The undissolved FITC-SILY can be attributed to insufficient 
mixing or a high concentration of FITC-SILY. Various chemicals can be used to enhance 
dissolving of the FITC-SILY.   
Both, a 1% bovine serum albumin (BSA) and 0.02% Tween 20 were 
independently used to block non-specific interactions between the FITC-SILY and the 
negative control microparticles. Also in attempt to reduce the hydrophobic interaction 
between the PLGA and the FITC, the molecular weight of the PLGA was reduced while 
increasing the molecular weight of the PEG. So, a methyl-PEG-PLGA with a molecular 
weight of 5,000:4,000 Da was purchased from Akina Inc and used to form the polymer 
shell of the negative control microparticles. However, the results of these experiments 
were not statistically different but brought this research one step closer to quantifying the 
attachment of the FITC-SILY.  
The most significant problem was that undissolved FITC-SILY was still present in 
the samples. In order to address this issue, Tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP-HCl) was added to the FITC-SILY solution to increase the solubility in PBS and 
the excess undissolved dye was removed with centrifugation prior to reaction with the 
microparticles. This experiment produced significantly different FITC-SILY 
concentrations between the experimental and negative control microparticles. A 
concentration of 0.0156mg/mL FITC-SILY with TCEP was determined to be the ideal 







of FITC-SILY attachment experiment further confirmed the successful attachment of 
FITC-SILY to the maleimides present on the surface of the microparticles. 
 
4.2.3 Validation of Microparticles’ Collagen Binding Capabilities 
The hypothesis of the validation of collagen binding experiment was that the 
SILY-MAL-PEG-PLGA microparticles would have significantly greater binding to type I 
collagen compared to the negative control (Me-PEG-PLGA) microparticles. The SILY 
was prepared at the ideal concentration of 0.0156mg/mL which was determined during 
the quantification experiments. The amount of microparticles bound to the type I collagen 
plate was significantly greater than the negative control microparticles. These results 
show that this microparticle system has significant clinical application in that it can bind 








4.3 Microparticle Degradation Observations 
Upon synthesis of initial microparticles, rapid degradation of the microparticles 
was observed. These initial microparticles contained the layers of PEG and PLGA 
without the conjugation of the collagen-binding peptide. The degradation of these 
particles was attributed to the presence of PEG on the surface of the microparticles and 
the inefficient packing of molecules within the microparticle. PEG is known to degrade at 
elevated temperature in the presence of oxygen and water through oxidation [6]. The 
solution for this problem was the incorporation of a dense core. For this reason, PLA was 
the chosen polymer based on biocompatibility and common use in drug delivery systems. 
The PLA forms a dense core by adding uniformity and tight packing to the core. Through 
the synthesis process, a 20% w/v PLA was the highest concentration of polymer that did 
not form a scum layer. A scum layer is produced when a polymer layer forms on top of 
the PVA template and adjoins all the microparticles together. This is highly undesirable 
and is prevented by ensuring that the polymer is evenly spread before the solvent 
evaporates. To further prevent degradation, a 5% w/v PLGA-PEG-Mal was chosen as the 
lowest concentration to provide polymer to each well with minimizing the 








4.4 Conclusions and Future Research 
The designed microparticle drug delivery system has the potential to target any 
type I collagen in the body, specifically atherosclerotic vessels. Further research should be 
conducted to synthesis 5µm microparticles using the currently available PDMS template by 
Akina, Inc. This size particle would allow for clearance of the venous system without 
occlusion [7]. Also, continued research should be performed with in-vitro testing to validate 
the biocompatibility and cytotoxicity of the microparticles with targeted cells. In-vivo testing 
should also be performed to analyze the biodistribution of the microparticles within the body. 
However, the expected biodistribution results should show targeting to type I collagen after 
the reduction of the particles’ size to 5µm.  
Impurities present in Figures 3.2-3.3 are shown among the microparticles. These 
impurities may be present due to excess PVA that was not properly dissolved and 
removed. Future studies should be performed to optimize the procedure in order to 
prevent these impurities potentially by increasing the time or temperature during PVA 
dissolving. 
Further research should be concluded to encapsulate drug within the PLGA core. 
Ideal drugs for this drug delivery system are drugs that require targeting to particular tissues 
or dugs with low solubility and low oral bioavailability. Hydrophobic drugs are known for 
their poor solubility in water. These drugs can be categorized as follows [8]: 
 Slightly soluble: 1-10mg/mL 
 Very slightly soluble: 0.1-1mg/mL 







Examples of PLGA based microparticles that have entered the market include: 
octreotide acetate, leuprolide acetate, triptorelin acetate, triptorelin pamoate, triptorelin, ect. 
[9]. Park et al. used the templating method to incorporate the hydrophobic drugs: felodipine, 
risperidone, progesterone, and paclitaxel [3]. Many different researchers have incorporated 
hydrophobic drugs into PLGA cores, but studies have also determined methods to 
incorporate hydrophilic drugs within the core. Gaignaux et al encapsulated anti-inflammatory 
and hydrophilic drug, Clonidine, into PLGA microparticles with the use of large aqueous 
phases to form the second water-in-oil-in-water (w/o/w) emulsion [10]. Further research 
including: scaling down the size of the microparticles, purifying the synthesized 
microparticles, and incorporating drug in the microparticle core will increase the clinical 
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